• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients.

作者信息

Schimpf Judith, Davidovic Tamara, Abbassi-Nik Armin, Sprenger-Mähr Hannelore, Lhotta Karl, Zitt Emanuel

机构信息

Department of Internal Medicine 3 (Nephrology and Dialysis), Academic Teaching Hospital LKH Feldkirch, Feldkirch, Austria.

Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.

出版信息

Transpl Int. 2022 Mar 22;36:10357. doi: 10.3389/ti.2022.10357. eCollection 2022.

DOI:10.3389/ti.2022.10357
PMID:35391899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8980220/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1baf/8980220/470fa59b4332/ti-35-10357-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1baf/8980220/470fa59b4332/ti-35-10357-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1baf/8980220/470fa59b4332/ti-35-10357-g001.jpg

相似文献

1
Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients.在接受mRNA疫苗初免的肾移植受者中，第三剂异源载体疫苗Ad26.COVS1接种后SARS-CoV-2抗体反应增强。
Transpl Int. 2022 Mar 22;36:10357. doi: 10.3389/ti.2022.10357. eCollection 2022.
2
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
3
Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients.肾移植受者在接种第三剂mRNA疫苗后对新冠病毒奥密克戎变异株的抗体反应欠佳。
Kidney Int. 2022 Jun;101(6):1282-1286. doi: 10.1016/j.kint.2022.04.009. Epub 2022 Apr 13.
4
Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.血液透析患者接种三剂 mRNA-BNT162b2 和腺病毒载体 Ad26COVS1 异源 SARS-CoV-2 疫苗后的体液和细胞免疫应答。
Front Immunol. 2022 Jun 23;13:907615. doi: 10.3389/fimmu.2022.907615. eCollection 2022.
5
Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients.肾和心脏移植受者接种 SARS-CoV-2 疫苗后产生供体特异性抗体。
Transpl Immunol. 2022 Dec;75:101722. doi: 10.1016/j.trim.2022.101722. Epub 2022 Sep 22.
6
A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients.第三剂 SARS-CoV-2 疫苗可提高实体器官移植受者对关注变异株的中和抗体。
Am J Transplant. 2022 Apr;22(4):1253-1260. doi: 10.1111/ajt.16933. Epub 2022 Jan 18.
7
The type of SARS-CoV-2 vaccine influences serological response in kidney transplant recipients.SARS-CoV-2 疫苗的种类会影响肾移植受者的血清学反应。
Clin Transplant. 2022 Apr;36(4):e14585. doi: 10.1111/ctr.14585. Epub 2022 Jan 18.
8
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
9
Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination.实体器官移植受者完成mRNA SARS-CoV-2疫苗接种后体液免疫反应不佳。
Clin Chem. 2021 Dec 30;68(1):251-253. doi: 10.1093/clinchem/hvab149.
10
Delayed kinetics of SARS-CoV-2 IgG antibody production in kidney transplant recipients following the third dose of COVID-19 vaccination.肾移植受者在接种第三剂新冠疫苗后，新冠病毒2型免疫球蛋白G抗体产生的动力学延迟
Clin Exp Nephrol. 2023 Jan;27(1):98-99. doi: 10.1007/s10157-022-02261-6. Epub 2022 Aug 5.

引用本文的文献

1
Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.肾移植受者 COVID-19 疫苗接种后抗受体结合域 IgG 抗体水平与 COVID-19 发病和严重程度的关系。
Viruses. 2024 Jan 12;16(1):114. doi: 10.3390/v16010114.
2
Measures to Increase Immunogenicity of SARS-CoV-2 Vaccines in Solid Organ Transplant Recipients: A Narrative Review.提高实体器官移植受者中SARS-CoV-2疫苗免疫原性的措施：一项叙述性综述
Vaccines (Basel). 2023 Nov 25;11(12):1755. doi: 10.3390/vaccines11121755.
3
Vaccinated kidney transplant recipients are yet not sufficiently protected against COVID-19.

本文引用的文献

1
Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients.与接种疫苗的肾移植患者相比，新冠康复者的体液免疫反应
Transpl Int. 2022 Jan 18;35:10060. doi: 10.3389/ti.2021.10060. eCollection 2021.
2
Homologous and Heterologous Covid-19 Booster Vaccinations.同源和异源 COVID-19 加强针接种。
N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26.
3
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.
接种疫苗的肾移植受者对新冠病毒仍未获得充分保护。
Nephrol Dial Transplant. 2023 Oct 31;38(11):2423-2425. doi: 10.1093/ndt/gfad127.
4
Effectiveness, Immunogenicity and Harms of Additional SARS-CoV-2 Vaccine Doses in Kidney Transplant Recipients: A Systematic Review.肾移植受者额外接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗剂量的有效性、免疫原性和危害：一项系统评价
Vaccines (Basel). 2023 Apr 18;11(4):863. doi: 10.3390/vaccines11040863.
5
Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.透析和肾移植患者接种 SARS-CoV-2 加强疫苗的疗效和安全性：系统评价和荟萃分析。
Int Urol Nephrol. 2023 Apr;55(4):791-802. doi: 10.1007/s11255-023-03471-x. Epub 2023 Feb 1.
6
[Not Available].[不可用]。
Nefrologia. 2022 Dec 16. doi: 10.1016/j.nefro.2022.12.006.
7
SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study.接种疫苗后英国有基础疾病的医护人员中的 SARS-CoV-2 抗体反应：一项队列研究。
BMJ Open. 2022 Dec 1;12(12):e066766. doi: 10.1136/bmjopen-2022-066766.
8
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.在未对两到三剂 mRNA 疫苗（RECOVAC）产生应答的肾移植受者中提高 COVID-19 疫苗免疫原性的替代策略：一项随机临床试验。
Lancet Infect Dis. 2023 Mar;23(3):307-319. doi: 10.1016/S1473-3099(22)00650-8. Epub 2022 Oct 27.
9
Comparison of the Immune Response After an Extended Primary Series of COVID-19 Vaccination in Kidney Transplant Recipients Receiving Standard Versus Mycophenolic Acid-sparing Immunosuppressive Regimen.接受标准免疫抑制方案与霉酚酸减量免疫抑制方案的肾移植受者在延长的新冠疫苗初级接种系列后的免疫反应比较
Transplant Direct. 2022 Oct 25;8(11):e1393. doi: 10.1097/TXD.0000000000001393. eCollection 2022 Nov.
接种同源或异源科兴疫苗或辉瑞疫苗后针对奥密克戎变异株 BA.1 的中和抗体。
Nat Med. 2022 Mar;28(3):486-489. doi: 10.1038/s41591-022-01704-7. Epub 2022 Jan 20.
4
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
5
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.英格兰延长 COVID-19 疫苗接种计划的血清学反应和疫苗效力。
Nat Commun. 2021 Dec 10;12(1):7217. doi: 10.1038/s41467-021-27410-5.
6
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
7
SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.SARS-CoV-2 疫苗接种在实体器官移植受者中的应用：临床医生需要了解的知识。
Transpl Int. 2021 Oct;34(10):1776-1788. doi: 10.1111/tri.14029. Epub 2021 Sep 20.